Version history

{
  "session_id": "sess-hyp-3a782e02e23e",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "llm",
  "action": "support",
  "content": "\n\n# Expert Assessment: TREM2 R47H Metabolic Lock-in at Cholesterol Ester Accumulation\n\n## Executive Summary\n\nThe hypothesis presents a mechanistically coherent framework connecting TREM2 R47H to microglial dysfunction via impaired lipid sensing and downstream ACAT1/LXR dysregulation. While the primary genetic link is robust, several translational gaps require attention before this can be considered a tractable therapeutic hypothesis.\n\n---\n\n## 1. Target Druggability Assessment\n\n### TREM2 (Primary Target)\n| Parameter | Assessment |\n|-----------|------------|\n| **Genetic Validation** | Strong - R47H represents one of the strongest genetic risk factors for LOAD (OR ~2-4) |\n| **Molecular Class** | Type I transmembrane receptor - highly tractable via biologics |\n| **Druggability Score** | **8/10** - Multiple modalities viable |\n| **Current Development Stage** | Humanized monoclonal antibodies in Phase 2 (AL002, others) |\n\nTREM2 is considered an attractive target due to its surface expression and extracellular ligand-binding domain. The R47H variant represents a **partial loss-of-function**, suggesting agonism rather than blockade may be the preferred strategy.\n\n### ACAT1 (Downstream Target)\n- **Druggability: Moderate** - Small molecule inhibitors exist (avasimibe, CI-1011)\n- **Challenge:** Systemic ACAT1 inhibition causes neurological side effects and has failed in atherosclerosis trials\n- **CNS penetration** remains a significant hurdle\n\n### LXR Pathway\n- **Druggability: Moderate** - Multiple agonists developed (T0901317, GW3965)\n- **Critical Limitation**: LXR agonists induce lipogenesis, precluding CNS clinical development\n- **Alternative**: LXRβ-selective modulators remain untested\n\n---\n\n## 2. Tool Compounds\n\n| Compound Class | Examples | CNS Penetration | Clinical Stage |\n|----------------|----------|-----------------|----------------|\n| Anti-TREM2 antibodies | AL002, BI-655404 | Limited | Phase 2 |\n| ACAT inhibitors | Avasimibe, CI-1011 | Unknown | Preclinical/Ph2 withdrawn |\n| LXR agonists | T0901317, GW3965 | High | Preclinical only |\n| T",
  "tokens_used": "518",
  "persona_id": "persona-domain_expert"
}